Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Cancer Vaccines01:30

Cancer Vaccines

370
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
370
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

5.1K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

923
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
923

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance.

Journal for immunotherapy of cancer·2024
Same author

CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency.

Breast cancer research : BCR·2024
Same author

Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing.

Journal for immunotherapy of cancer·2024
Same author

Predicting the Abscopal Phenomenon-Letter to the Editor.

Molecular cancer therapeutics·2024
Same author

BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.

Cancer gene therapy·2023
Same author

TGF-β: the apex predator of immune checkpoints.

Future oncology (London, England)·2023

Related Experiment Video

Updated: Jul 7, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K

Commentary on oncolytic viruses: past, present, and future.

Christopher Larson1, Bryan Oronsky2, Tony R Reid1

  • 1EpicentRx Inc, La Jolla, California, USA.

Journal for Immunotherapy of Cancer
|December 22, 2023
PubMed
Summary

Oncolytic viruses (OVs) show promise for cancer treatment but have faced declining interest. This commentary addresses misconceptions and offers reasons for renewed optimism in anticancer virotherapy.

Keywords:
lymphocyte activationoncolytic viruses

More Related Videos

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

6.6K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

12.7K

Related Experiment Videos

Last Updated: Jul 7, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

6.6K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

12.7K

Area of Science:

  • Oncology
  • Virology
  • Biotechnology

Background:

  • Oncolytic viruses (OVs) experienced peak popularity in the early 2000s and a resurgence in 2015 with FDA approval of talimogene laherparepvec.
  • Despite pharmaceutical development, OVs have largely fallen out of favor, entering a 'trough of disillusionment'.

Purpose of the Study:

  • To enumerate and address misconceptions surrounding oncolytic virus therapy.
  • To provide a balanced perspective on the current state of anticancer virotherapy.
  • To identify reasons for optimism in the field of OVs.

Main Methods:

  • This is a commentary, not an experimental study.
  • Analysis of historical trends and perceptions in oncolytic virus research.
  • Discussion of current challenges and future directions in anticancer virotherapy.

Main Results:

  • The field of oncolytic virotherapy is characterized by specific conceptions, perceptions, and misconceptions.
  • Several factors contribute to the current 'trough of disillusionment' for OVs.
  • Despite challenges, there are grounds for optimism regarding the future of OV-based cancer treatments.

Conclusions:

  • Addressing misconceptions is crucial for advancing oncolytic virus therapy.
  • Renewed interest and development in OVs are warranted.
  • Anticancer virotherapy holds significant potential for future cancer treatment strategies.